Results 31 to 40 of about 135,267 (266)

Visceral leishmaniasis patients display altered composition and maturity of neutrophils as well as impaired neutrophil effector functions [PDF]

open access: yes, 2016
Immunologically, active visceral leishmaniasis (VL) is characterised by profound immunosuppression, severe systemic inflammatory responses and an impaired capacity to control parasite replication.
Adem, E   +19 more
core   +3 more sources

The potential role and apoptotic profile of three medicinal plant extracts on Leishmania tropica by MTT assay, macrophage model and flow cytometry analysis

open access: yesParasite Epidemiology and Control, 2021
Introduction: Treatment of leishmaniasis with conventional synthetic drugs is a major global challenge. This study was designed to explore the leishmanicidal activity and apoptotic profile of three leaf extracts on Leishmania tropica stages. Methods: The
Mozhde Ilaghi   +8 more
doaj   +1 more source

Rapid Detection of Leishmania infantum Infection in Dogs: Comparative Study Using an Immunochromatographic Dipstick Test, Enzyme-Linked Immunosorbent Assay, and PCR [PDF]

open access: yes, 2002
Current zoonotic visceral leishmaniasis (ZVL) control programs in Brazil include the culling of Leishmania infantum-infected reservoir dogs, a strategy that has failed to prevent a rise of canine and human ZVL cases over the past decade.
Bruce Alex   +8 more
core   +3 more sources

Anti-Leishmanial and Immunomodulatory Effects of Epigallocatechin 3-O-Gallate on Leishmania tropica: Apoptosis and Gene Expression Profiling

open access: yesIranian Journal of Parasitology, 2019
Background: Pentavalent antimonials such as meglumine antimoniate (MA, Glucantime), are the first-line treatment against leishmaniasis, but at present, they have basically lost their efficacy. This study was aimed to explore epigallocatechin 3-O-gallate (
Morteza SADUQI   +14 more
doaj   +1 more source

The recombinant cysteine proteinase B (CPB) from Leishmania braziliensis and its domains: promising antigens for serodiagnosis of cutaneous and visceral leishmaniasis in dogs. [PDF]

open access: yes, 2019
Leishmaniasis represents a group of parasitic diseases caused by a protozoan of the genus Leishmania and is widely distributed in tropical and subtropical regions.
Basombrío, Manuel Alberto   +10 more
core   +1 more source

Increasing incidence of zoonotic visceral leishmaniasis on Crete, Greece [PDF]

open access: yes, 2009
To determine whether the incidence of canine leishmaniasis has increased on Crete, Greece, we fitted infection models to serodiagnostic records of 8,848 dog samples for 1990–2006.
Adler   +19 more
core   +4 more sources

Leishmaniasis [PDF]

open access: yesThe Lancet, 1999
In 1903, Leishman and Donovan separately described the protozoan now called Leishmania donovani in splenic tissue from patients in India with the life-threatening disease now called visceral leishmaniasis. Almost a century later, many features of leishmaniasis and its major syndromes (ie, visceral, cutaneous, and mucosal) have remained the same; but ...
openaire   +2 more sources

Leishmania: Responding to environmental signals and challenges without regulated transcription

open access: yesComputational and Structural Biotechnology Journal, 2020
Here we describe the non-canonical control of gene expression in Leishmania, a single-cell parasite that is responsible for one of the major neglected tropical diseases.
Janne Grünebast, Joachim Clos
doaj   +1 more source

The burden of neglected tropical diseases in Ethiopia, and opportunities for integrated control and elimination [PDF]

open access: yes, 2012
Background: Neglected tropical diseases (NTDs) are a group of chronic parasitic diseases and related conditions that are the most common diseases among the 2·7 billion people globally living on less than US$2 per day.
A Alemu   +103 more
core   +2 more sources

Biomaterial Strategies for Targeted Intracellular Delivery to Phagocytes

open access: yesAdvanced Functional Materials, EarlyView.
Phagocytes are essential to a functional immune system, and their behavior defines disease outcomes. Engineered particles offer a strategic opportunity to target phagocytes, harnessing inflammatory modulation in disease. By tuning features like size, shape, and surface, these systems can modulate immune responses and improve targeted treatment for a ...
Kaitlyn E. Woodworth   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy